Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5369-5371

  Belley, Adam ^a   McKay, Geoffrey A ^a   Arhin, Francis F ^a   Sarmiento, Ingrid ^a   Beaulieu, Sylvain ^a   Fadhil, Ibthihal ^a   Parr Jr , Thomas R ^a   Moeck, Gregory ^a  

^a The Medicines Company   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DECHLOROEREMOMYCIN; ORITAVANCIN; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL DEATH; CELL VIABILITY; MEMBRANE DEPOLARIZATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; GLYCOPEPTIDES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 78649671049     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00760-10     Document Type: Article

References (18)

1. Appelbaum, P. C. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:398-408. (Pubitemid 47498971)
2. Arhin, F. F., D. C. Draghi, C. M. Pillar, T. R. Parr, Jr., G. Moeck, and D. F. Sahm. 2009. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob. Agents Chemother. 53:4762-4771.
3. Arhin, F. F., I. Sarmiento, T. R. Parr, Jr., and G. Moeck. 2009. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J. Antimicrob. Chemother. 64:868-870.
4. Belley, A., E. Neesham-Grenon, G. McKay, F. F. Arhin, R. Harris, T. Beveridge, T. R. Parr, Jr., and G. Moeck. 2009. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 53:918-925.
5. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, CLSI document M7-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Courvalin, P. 2006. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42(Suppl. 1):S25-S34.
7. Domenech, O., G. Francius, P. M. Tulkens, F. Van Bambeke, Y. Dufrene, and M. P. Mingeot-Leclercq. 2009. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: effect on membrane permeability and nanoscale lipid membrane organization. Biochim. Biophys. Acta 1788:1832-1840.
8. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
9. Kim, S. J., L. Cegelski, D. Stueber, M. Singh, E. Dietrich, K. S. Tanaka, T. R. Parr, Jr., A. R. Far, and J. Schaefer. 2008. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J. Mol. Biol. 377:281-293.
10. Kim, S. J., M. Singh, and J. Schaefer. 2009. Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus. J. Mol. Biol. 391:414-425.
11. Lunde, C. S., S. R. Hartouni, J. W. Janc, M. Mammen, P. P. Humphrey, and B. M. Benton. 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53:3375-3383.
12. Mascio, C. T., J. D. Alder, and J. A. Silverman. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51:4255-4260.
13. McKay, G. A., S. Beaulieu, F. F. Arhin, A. Belley, I. Sarmiento, T. Parr, Jr., and G. Moeck. 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 63:1191-1199.
14. McKay, G. A., I. Fadhil, S. Beaulieu, S. Ciblat, A. R. Far, G. Moeck, and T. R. Parr, Jr. 2006. Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci, abstr. C1-682, p. 76. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. Patti, G. J., S. J. Kim, T. Y. Yu, E. Dietrich, K. S. Tanaka, T. R. Parr, Jr., A. R. Far, and J. Schaefer. 2009. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J. Mol. Biol. 392:1178-1191.
16. Rodriguez, M. J., N. J. Snyder, M. J. Zweifel, S. C. Wilkie, D. R. Stack, R. D. Cooper, T. I. Nicas, D. L. Mullen, T. F. Butler, and R. C. Thompson. 1998. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci. J. Antibiot. (Tokyo) 51:560-569.
17. Rybak, M., B. Lomaestro, J. C. Rotschafer, R. Moellering, Jr., W. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
18. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.